International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 573-577 , June 2010

Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis

  • Takashi Deguchi

      Affiliations

    • Department of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 58 230 6338; fax: +81 58 230 6339.
    • ,
  • Keita Nakane

      Affiliations

    • Department of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan
    • ,
  • Mitsuru Yasuda

      Affiliations

    • Department of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan
    • ,
  • Takako Shimizu

      Affiliations

    • Translational Medicine & Clinical Pharmacology Department, R&D Division, Daiichi Sankyo Co., Ltd., 3-5-1 Nihonbashi Hon-Cho, Chuo-Ku, Tokyo 103-8426, Japan
    • ,
  • Koichi Monden

      Affiliations

    • Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-Cho, Kita-Ku, Okayama 700-8558, Japan
    • ,
  • Soichi Arakawa

      Affiliations

    • Division of Urology, Department of Surgery Related, Faculty of Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe 650-0017, Japan
    • ,
  • Tetsuro Matsumoto

      Affiliations

    • Department of Urology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu 807-8555, Japan

Received 4 November 2009 ,Accepted 3 February 2010.

References 

  1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10
  2. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Infect Control. 2006;34(Suppl. 1):S38–S45
  3. Craig WA. Does the dose matter?. Clin Infect Dis. 2001;33(Suppl. 3):S233–S237
  4. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073–1081
  5. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45:2793–2797
  6. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother. 2003;52:668–674
  7. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004;189:1590–1597
  8. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med. 1974;291:1159–1163
  9. Miller LG, Mehrotra R, Tang AW. Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections?. Int J Antimicrob Agents. 2007;29:605–607
  10. Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents. 2002;19:546–553
  11. Wagenlehner FM, Weidner W, Naber KG. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations. J Hosp Infect. 2005;60:191–200
  12. Matsumoto T, Yasuda M, Arakawa S, Monden K, Muratani T, Hori S. Clinical response of levofloxacin 500mg qd to complicated urinary tract infection—efficacy of 7- and 14-day administration. Jpn J Chemother. 2009;57(Suppl. 2):34–46
  13. Tanigawara Y, Shimizu T, Totsuka K. Population pharmacokinetics and pharmacodynamics of 500mg oral dose levofloxacin in respiratory tract infection patients. Jpn J Chemother. 2009;57(Suppl. 2):47–54
  14. Wagenlehner FME, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500mg) versus ciprofloxacin (500mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents. 2006;28:551–559
  15. Naightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy. 2000;46(Suppl. 1):6–14
  16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI; 2007.
  17. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases. http://www.eucast.org/clinical_breakpoints/ [accessed 10 February 2010].
  18. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46:669–683
  19. Stein GE, Schooley SL, Nicolau DP. Urinary bacterial activity of single doses (250, 500, 750 and 1000mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Int J Antimicrob Agents. 2008;32:320–325
  20. Wagenlehner FME, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Naber KG. Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother. 2006;50:3947–3949
  21. Wagenlehner FME, Wagenlehner C, Redman R, Weidner W, Naber KG. Urinary bactericidal activity of doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother. 2009;53:1567–1573

PII: S0924-8579(10)00076-2

doi: 10.1016/j.ijantimicag.2010.02.004

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 573-577 , June 2010

Article Tools